Investors

TSXV: NRX

From acute injury to functional recovery

Nurexone's mission is to pioneer development of novel, biologic and minimally-invasive treatment for Spinal Cord and Traumatic Brain Injuries

We're developing a nanocarrier - based platform that uses exosomes to deliver specialized therapeutic compounds to the body.

Get Investor Updates

Press releases

June 4, 2024

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

May 29, 2024

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

May 17, 2024

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

In THE MEDIA

August 30, 2023
ICE
נוראקסון השלימה סבב גיוס נוסף כחלק מהיערכות לניסויים הקליניים
August 28, 2023
BizPortal
חברת נוראקסון הישראלית השלימה סיבוב השקעה נוסף של 1.3 מיליון דולר קנדי
June 22, 2023
LinkedIn
Great professional analysis report has been published!

Presentations

FINANCIALS​

2024

May 29, 2024
Q1FY24 Interim MD&A
May 29, 2024
Q1FY24 Interim Financial Statements

2023

April 2, 2024
2023 Audited Annual FS
April 2, 2024
2023 Audited Annual MD&A
November 24, 2023
Q3 - 2023 interim FS
November 24, 2023
Q3 - 2023 Interim MD&A
August 25, 2023
Q2 - 2023 interim FS
August 25, 2023
Q2 - 2023 Interim MD&A
May 23, 2023
Q1 - 2023 Interim FS
May 23, 2023
Q1 - 2023 Interim MD&A

2022

March 31, 2023
Q4FY22 Annual FS
March 30, 2023
Q4FY22 Annual Information Form
March 29, 2023
Q4FY22 Annual MD&A
November 10, 2022
Management Information Circular
September 30, 2022
Q3-2022 interim FS
September 30, 2022
Q3-2022 MD&A
June 30, 2022
Q2-2022 interim FS
June 30, 2022
Q2-2022 MD&A
May 12, 2022
NurExone Biologic Inc @ Filing statement
””

Set layout popup